- Public Comps
- Ventyx Biosciences
Ventyx Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ventyx Biosciences and similar public comparables like SSY Group, MedinCell, Arbutus Biopharma, Immix Biopharma and more.
Ventyx Biosciences Overview
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Founded
2018
HQ

Employees
82
Website
Financials (FY)
EV
$822M
Valuation Multiples
Start free trialVentyx Biosciences Financials
Ventyx Biosciences reported last fiscal year revenue of - and negative EBITDA of ($120M).
In the same fiscal year, Ventyx Biosciences generated - in gross profit, ($120M) in EBITDA losses, and had net loss of ($143M).
Revenue (LTM)
Ventyx Biosciences P&L
In the most recent fiscal year, Ventyx Biosciences reported revenue of - and EBITDA of ($120M).
Ventyx Biosciences is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
Ventyx Biosciences Stock Performance
Ventyx Biosciences has current market cap of $1B, and enterprise value of $822M.
Market Cap Evolution
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $822M | $1B | - | - | - | - | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVentyx Biosciences Valuation Multiples
Ventyx Biosciences trades at (6.9x) EV/EBITDA.
Ventyx Biosciences Financial Valuation Multiples
As of September 2, 2026, Ventyx Biosciences has market cap of $1B and EV of $822M.
Ventyx Biosciences has a P/E ratio of (7.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ventyx Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ventyx Biosciences Margins & Growth Rates
Ventyx Biosciences grew EBITDA by 9% in the last fiscal year.
Ventyx Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ventyx Biosciences Operational KPIs
Ventyx Biosciences' revenue per employee in the last FY averaged $0.0M.
Data powered by FactSet, Inc. and Morningstar, Inc.
Ventyx Biosciences Competitors
Ventyx Biosciences competitors include SSY Group, MedinCell, Arbutus Biopharma, Immix Biopharma, GuangYuYuan Chinese, Strides Pharma, Avalo Therapeutics, Changchun BCHT, Chengdu Kanghua and SPIMACO - ADDWAEIH.
Most Ventyx Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.5x | - | 9.3x | - | |||
| 43.2x | 26.8x | (35.1x) | (114.8x) | |||
| 65.2x | 7.2x | (24.8x) | - | |||
| - | - | (25.9x) | (18.9x) | |||
| 4.6x | - | 41.7x | - | |||
| 2.4x | 2.1x | 11.1x | 11.1x | |||
| 10454.1x | 31797.8x | (7.5x) | - | |||
| 11.6x | 11.8x | (35.1x) | (39.4x) | |||
This data is available for Pro users. Sign up to see all Ventyx Biosciences competitors and their valuation data. Start Free Trial | ||||||
Ventyx Biosciences VC Funding History
Before going public, Ventyx Biosciences raised $165M in total equity funding, across 2 rounds.
Ventyx Biosciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ventyx Biosciences
| When was Ventyx Biosciences founded? | Ventyx Biosciences was founded in 2018. |
| Where is Ventyx Biosciences headquartered? | Ventyx Biosciences is headquartered in United States. |
| How many employees does Ventyx Biosciences have? | As of today, Ventyx Biosciences has over 82 employees. |
| Who is the CEO of Ventyx Biosciences? | Ventyx Biosciences' CEO is Raju S. Mohan. |
| Is Ventyx Biosciences publicly listed? | Yes, Ventyx Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Ventyx Biosciences? | Ventyx Biosciences trades under VTYX ticker. |
| When did Ventyx Biosciences go public? | Ventyx Biosciences went public in 2021. |
| Who are competitors of Ventyx Biosciences? | Ventyx Biosciences main competitors include SSY Group, MedinCell, Arbutus Biopharma, Immix Biopharma, GuangYuYuan Chinese, Strides Pharma, Avalo Therapeutics, Changchun BCHT, Chengdu Kanghua, SPIMACO - ADDWAEIH. |
| What is the current market cap of Ventyx Biosciences? | Ventyx Biosciences' current market cap is $1B. |
| Is Ventyx Biosciences profitable? | No, Ventyx Biosciences is not profitable. |
| How many companies Ventyx Biosciences has acquired to date? | Ventyx Biosciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Ventyx Biosciences has invested to date? | Ventyx Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Ventyx Biosciences
Lists including Ventyx Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




